statement
Novo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.
A statement by 诺和诺德. Statements are as reported by the cited publishers — not verified by DecisionGateway.
诺和诺德宣布，其新药卡瑞林肽司美格鲁肽注射液（CagriSema）用于长期体重管理的上市申请获国家药监局受理。
Related claims
CagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statementCagriSema is a fixed-dose combination formulation.界面新闻 · statementCagriSema is injected subcutaneously once weekly.界面新闻 · statementThe FDA requires a warning about a risk of sudden blindness with popular weight-loss drugs.noticias_telemundo · statementThe two components act through different and complementary mechanisms of action, jointly acting on appetite and weight-regulation pathways.界面新闻 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statement
More claims by 诺和诺德
No other claims by this actor on record.